All In Biotech

Drug Trial Radar · NCT03981536

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

A Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

18

Planned (sponsor's estimate)

Start

Oct 10, 2019

Primary completion

Nov 2, 2020

Study completion Nov 2, 2020

Sponsor

Lead sponsor
AL-S PharmaIndustry
Sponsor type
Industry
First posted
Jun 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Single ascending doses of AP-101 will be administered by intravenous (IV) infusion

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • AP-101Drug

    Administered by intravenous infusion (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With One or More Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs)Time frame: Baseline up to day 84
  2. Number of participants with abnormalities in vital signs, clinical laboratory assessments, physical or neurological examinations, or electrocardiograms (ECGs)Time frame: Baseline up to day 84

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • London Health Sciences Centre, University Hospital

    London, Ontario, Canada

  • Sunnybrook Health Sciences Centre, Toronto

    Toronto, Ontario, Canada

  • Montreal Neurological Institute & Hospital

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.